Given liver biopsy risks and limitations [49], there is an ongoing search for noninvasive biomarker for NAFLD, with multiple biomarkers have been recently proposed including betatrophin and fetuin-A [50,51]. Here, ANGPTL8 is linked to metabolic dysfunction-associated steatotic liver disease.